Email this article Effects of trimetazidine and perindopril on myocardialfunction and metabolism in postmyocardial infarction patients with cardiac failure
- Authors: Shabrov AV1, Arkharov IV1, Burbello АТ1, Makhnov AP1
-
Affiliations:
- Issue: Vol 78, No 9 (2003)
- Pages: 77-82
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/29667
- ID: 29667
Cite item
Full Text
Abstract
Aim. To investigate effects of trimetazidine and perindopril on myocardial function and metabolism in
patients with cardiac failure after myocardial infarction.
Material and methods. A comparative study was made of the effects of 6-month therapy with perindopril,
trimetazidine alone and in combination on clinical symptoms, left ventricular function and perfusion,
glucose utilization, excretion and utilization of fatty acids in the zones of postinfarction scar,
periinfarction ischemia and in without infarction changes.
Results. Combined treatment with the ACE inhibitor and trimetazidine produced positive clinical and
functional-metabolic shifts in postmyocardial infarction patients with cardiac failure.
Conclusion. The addition to the program of mild cardiac failure treatment early after myocardial infarction
of an ACE inhibitor and a cytoprotective drug (trimetazidine) promotes more complete clinical
compensation of the patients.
patients with cardiac failure after myocardial infarction.
Material and methods. A comparative study was made of the effects of 6-month therapy with perindopril,
trimetazidine alone and in combination on clinical symptoms, left ventricular function and perfusion,
glucose utilization, excretion and utilization of fatty acids in the zones of postinfarction scar,
periinfarction ischemia and in without infarction changes.
Results. Combined treatment with the ACE inhibitor and trimetazidine produced positive clinical and
functional-metabolic shifts in postmyocardial infarction patients with cardiac failure.
Conclusion. The addition to the program of mild cardiac failure treatment early after myocardial infarction
of an ACE inhibitor and a cytoprotective drug (trimetazidine) promotes more complete clinical
compensation of the patients.
Keywords
References
- Алехин М. Е., Божьев А. М., Морозова Ю. А. и др. Дисфункция левого желудочка по данным стресс-эхокардиографии с добутамином у больных острым инфарктом миокарда (на 3-й неделе заболевания). Кардиология 2001; 41(7): 34-38.
- Мареев В. Ю., Беленков Ю. И. Перспективы в лечении хронической сердечной недостаточности. Сердеч. недостаточность 2002; 3 (3(13)): 109-114.
- Рекомендации Европейского общества кардиологов. Рекомендации по диагностике и лечению хронической сердечной недостаточности. Там же 2001; 2 (6): 251-276.
- ACC/AHA/ACP-ASIM. Guidelines for the management of patients with chronic stable angina. J. Am.Coll.Cardiol. 1999; 33: 2029-2197.
- Савичева И. Ю., Рыжкова Д. В., Тютин Л. А. Применение ПЭТ с новым радиофармпрепаратом бутиратом натрия для оценки состояия миокарда у пациентов с ИБС. Вестн. рентгенол. 1999; 5: 18-21.
- Brottier L., Barat J. L., Combe C. et al. Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy. Eur. Heart J. 1990; 11: 207-212.
- Fantini E., Aihias P., Demaison L., Crynberg A. Protective effects of trimetazidine on hypoxic cardiac myocytes from the rat. Fundam. Clin. Pharmacol. 1997; 11 (5): 427-439.
- Kober G., Buck Т., Sievert H., Vallbracht C. Myocardial protection during percutaneous transluminal coronary angioplasty: effect of trimetazidine. Eur. Heart J. 1992; 13 (8): 1109-1115.
- Birand A., Kudaiberdieva G. Z., Batyraliev T. A. et al. Effects of trimetazidine in heart rate variability and left ventricular systolic perfomance in patients with coronary artery disease after percutaneous transluminal angioplasty. Angiology 1997; 8 (5): 413-422.
- Jackson G. Angina, myocardial hibernation and trimetazidine.Int. J. Clin. Pract. 1997; 51(6): 347-358.
- Pornin M. Lack of effects of trimetazidine in systemic hemidynamic. Clin. Trials Metaanal. 1994; 29: 49-56.
- Моисеев В. С, Барышников А. Ю., Терещенко С. И. и др. Влияние триметазидина на апоптоз и иммунологический фенотип у больных с острым инфарктом миокарда и застойной сердечной недостаточностью. Кардиология 1998; 38 (6): 40-43.
- Терещенко С. Н., Акимова О. С, Демидова И. В. и др. Цитопротектор триметазидин в комплексной терапии тяжелой постинфарктной хронической сердечной недостаточности. Там же 1999; 39 (9): 48-52.
- Терещенко С. Н., Александрия Л. Г., Моисеев В. С. Возможности применения триметазидина в комплексной терапии инфаркта миокарда, осложненного левожелудочковой недостаточностью. Там же 2002; 42 (10): 19-21.
- Effects of trimetazidine on contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischemic cardiomyopathy. Eur. Heart. J. 2002; 22: 2164-2170.
- Stanley W. C., Lopaschuk G. D., Hall J. L., McCormack J. G. Regulation of myocardial carbohydrate metabolism under normal and ischemic conditions: potential for pharmacological interventions. Cardiovasc. Res. 1997; 33 (2): 243-257.
- Veitch K., Maisin L., Hue L. Trimetazidine effects on the damаge to mitochondrial functions caused by ischemia and reperfusion. Am. J. Cardiol. 1995; 76 (6): 25B-30B.
- Sentex E., Sergiel J. P., Lucien A., Grinberg A. Trimetazidine increases phospholipid turnover in ventricular myocyte. Mol. Cell. Biochem. 1997; 175: 153-162.
Supplementary files
